Ocular Therapeutix (OCUL) Gains from Investment Securities: 2013-2025
Historic Gains from Investment Securities for Ocular Therapeutix (OCUL) over the last 8 years, with Mar 2025 value amounting to $1.0 million.
- Ocular Therapeutix's Gains from Investment Securities fell 81.98% to $1.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $1.0 million, marking a year-over-year decrease of 81.98%. This contributed to the annual value of $19.9 million for FY2024, which is 23.24% up from last year.
- Ocular Therapeutix's Gains from Investment Securities amounted to $1.0 million in Q1 2025, which was down 94.73% from $19.9 million recorded in Q4 2024.
- In the past 5 years, Ocular Therapeutix's Gains from Investment Securities registered a high of $19.9 million during Q4 2024, and its lowest value of -$2,000 during Q1 2022.
- Its 3-year average for Gains from Investment Securities is $4.3 million, with a median of $1.0 million in 2025.
- In the last 5 years, Ocular Therapeutix's Gains from Investment Securities slumped by 100.08% in 2022 and then surged by 581,674.60% in 2024.
- Ocular Therapeutix's Gains from Investment Securities (Quarterly) stood at $6.8 million in 2021, then slumped by 97.24% to $187,000 in 2022, then spiked by 46.52% to $274,000 in 2023, then skyrocketed by 7,158.28% to $19.9 million in 2024, then plummeted by 81.98% to $1.0 million in 2025.
- Its Gains from Investment Securities was $1.0 million in Q1 2025, compared to $19.9 million in Q4 2024 and $1.8 million in Q3 2024.